Shanghai Shyndec Pharmaceutical Co., Ltd.

SSE:600420.SS

10.75 (CNY) • At close June 6, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001
Revenue 10,937.52511,931.8112,959.32113,944.94812,556.28212,199.10711,320.7818,517.7549,125.7752,682.2452,748.8362,349.7482,006.8921,702.6231,422.9641,164.234687.232624.323545.871502.746358.532382.913227.584149.102
Cost of Revenue 6,645.2147,537.5458,024.5637,848.1416,645.2876,138.835,798.9344,826.6445,826.8361,358.3491,473.7961,368.7971,330.0781,173.537987.463817.92436.525397.717354.923316.3216.256262.177137.93468.558
Gross Profit 4,292.3114,394.2654,934.7586,096.8075,910.9956,060.2775,521.8483,691.1093,298.9391,323.8961,275.04980.951676.814529.086435.501346.314250.707226.605190.947186.446142.276120.73689.6580.544
Gross Profit Ratio 0.3920.3680.3810.4370.4710.4970.4880.4330.3610.4940.4640.4170.3370.3110.3060.2970.3650.3630.350.3710.3970.3150.3940.54
Reseach & Development Expenses 575.93569.432520.923589.185498.928417.166373.644319.166340.33481.43293.87485.79250.40736.68841.043000000000
General & Administrative Expenses 154.539156.914125.713146.138111.614110.964119.216117.581134.84734.16142.20324.57717.50313.28113.70297.90984.43843.81659.2753.88143.58539.00728.08234.223
Selling & Marketing Expenses 873.5981,849.3422,746.3413,484.783,396.813,609.653,242.7191,489.8771,009.502584.938645.91518.539338.777235.884163.691124.49183.10655.96157.11355.42840.75641.75730.75626.547
SG&A 1,028.1382,782.9632,872.0543,630.9183,508.4243,720.6143,361.9341,607.4581,144.348619.098688.113543.116356.281249.165177.393222.4167.54399.776116.382109.30984.34180.76458.83860.77
Other Expenses 936.32-22.987593.901654.626619.99672.16534.1157.407138.26817.08748.88636.4615.95516.14914.54214.4876.3372.6442.6253.7771.8131.1133.7983.034
Operating Expenses 2,540.3873,544.293,986.8774,874.7294,627.3424,809.9444,440.7712,518.8322,084.667882.315953.291765.278490.599358.444288.089225.917169.838102.193117.844110.51685.21581.53359.5661.35
Operating Income 1,751.9241,081.627966.1351,247.1561,024.1941,031.0861,259.821946.378907.817337.69252.968180.168169.993153.741139.517111.41477.215128.51275.12279.25355.57936.99430.0418.103
Operating Income Ratio 0.160.0910.0750.0890.0820.0850.1110.1110.0990.1260.0920.0770.0850.090.0980.0960.1120.2060.1380.1580.1550.0970.1320.121
Total Other Income Expenses Net -78.8714.93217.985-318.30816.93341.7711.995-9.357138.12968.09144.17236.20214.18415.84714.54214.4870.4822.6442.5071.9151.5951.0623.332.777
Income Before Tax 1,673.0541,096.56984.12918.2091,041.1271,072.8551,293.936953.7841,036.513352.627297.14216.37185.186169.588154.058125.90183.551131.15677.62981.16857.17438.05633.3720.88
Income Before Tax Ratio 0.1530.0920.0760.0660.0830.0880.1140.1120.1140.1310.1080.0920.0920.10.1080.1080.1220.210.1420.1610.1590.0990.1470.14
Income Tax Expense 340.974131.949116.63597.063141.08144.388223.957135.212182.48161.07249.60528.85533.51622.6720.93817.19810.9718.04811.34410.6378.5194.8176.9523.591
Net Income 1,083.623691.88867.485821.146900.047928.467705.522515.803476.934221.053189.991132.788115.945120.033108.11189.05253.91494.0350.49858.68636.8323.43321.89714.575
Net Income Ratio 0.0990.0580.0670.0590.0720.0760.0620.0610.0520.0820.0690.0570.0580.070.0760.0760.0780.1510.0930.1170.1030.0610.0960.098
EPS 0.810.540.840.80.880.90.650.460.430.560.330.230.220.210.190.150.10.160.0880.10.0640.0660.0380.025
EPS Diluted 0.810.540.750.70.760.810.650.460.430.560.330.230.220.210.190.150.10.160.0880.10.0640.0660.0380.025
EBITDA 2,482.2591,978.1721,939.2531,848.9421,891.0521,984.6932,225.5681,995.3032,052.753633.174460.021316.985262.236218.517187.856153.806107.587154.39397.0698.43670.39239.99134.40421.404
EBITDA Ratio 0.2270.1660.150.1330.1510.1630.1970.2340.2250.2360.1670.1350.1310.1280.1320.1320.1570.2470.1780.1960.1960.1040.1510.144